ArticleNeurology(R) neuroimmunology & neuroinflammation2019
Clinical utility of a molecular signature in inflammatory demyelinating disease.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Impact of Anti-CD20 Therapies on Cytokine, Chemokine and Adhesion Molecule Dynamics in Multiple Sclerosis: A Narrative Review.Neurology and therapy · 2026Review
- CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.Journal of neurology · 2025Review
- CXCL13 as a Biomarker: Background and Utility in Multiple Sclerosis.Biomolecules · 2024Review
- Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Recent Advances in Biosensors for Diagnosis of Autoimmune Diseases.Sensors (Basel, Switzerland) · 2024Review
- Diagnostic potential of blood-based biomarkers in multiple sclerosis.Frontiers in neurology · 2024Article
- The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome.International journal of molecular sciences · 2023Article
- Recent Trends in Metal Nanoparticles Decorated 2D Materials for Electrochemical Biomarker Detection.Biosensors · 2023Review
- The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy.Biomedicines · 2022Review
- Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects.Journal of personalized medicine · 2022Review
- [Diagnostic Value of Locally Produced Tumor Markers and Blood Brain Barrier Integrity in Lung Cancer Patients with Leptomeningeal Metastasis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on "Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function".Fluids and barriers of the CNS · 2021Article
- The Neuroimmunology of Multiple Sclerosis: Fictions and Facts.Frontiers in neurology · 2021Review
- The Evolution of Neurofilament Light Chain in Multiple Sclerosis.Frontiers in neuroscience · 2021Review
- Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction.Fluids and barriers of the CNS · 2020Article
- Molecular biomarkers in multiple sclerosis.Journal of neuroinflammation · 2019Review
- Vitamin D enhances responses to interferon-β in MS.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We sought to develop molecular biomarkers of intrathecal inflammation to assist neurologists in identifying patients most likely to benefit from a range of immune therapies. Methods: We used Luminex technology and index determination to search for an inflammatory activity molecular signature (IAMS) in patients with inflammatory demyelinating disease (IDD), other neuroinflammatory diagnoses, and noninflammatory controls. We then followed the clinical characteristics of these patients to find how the presence of the signature might assist in diagnosis and prognosis. Results: A CSF molecular signature consisting of elevated CXCL13, elevated immunoglobulins, normal albumin CSF/serum ratio (Q Conclusions: A CSF IAMS may prove useful in the diagnosis and management of patients with IDD and other neuroinflammatory syndromes. Classification of evidence: This study provides Class IV evidence that a CSF IAMS identifies patients with IDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.